• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    AGC Biologics Appoints Jun Takami GM of Chiba Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Alkermes, Merck Enter Clinical Trial and Supply Agreement

    Sterling Pharma Solutions Acquires ADC Biotechnology

    Moderna, Catalent Enter Long-Term Strategic Vax Pact
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    Agilex Biolabs Acquires TetraQ for APAC Expansion Plans

    Alkermes, Merck Enter Clinical Trial and Supply Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market

    Metrics Contract Services Completes Russian Regulatory Inspection
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Reed-Lane

    Adare Pharma Solutions

    PCI Pharma Services

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Syngene

    Baxter BioPharma Solutions

    Quotient Sciences

    Reed-Lane

    Adare Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    2015 in Review: 6 Key Trends Affecting CMOs

    A look at major CMO trends ranging from budgets to growth opportunities

    Related CONTENT
    • The Ever-Evolving World of Combination Products
    • Embedding Your Drug Strategy Within a Solid Foundation for Success
    • Sepha Launches Small Batch Contract Packaging Service
    • A Potential “Marriage”
    • Injectables Firms Expand Capacity
    Eric S. Langer, BioPlan Associates11.17.15
    Biopharmaceutical manufacturing outsourcing continues to expand, both domestically and globally. Contract manufacturing organizations (CMOs) are benefiting from expanding economies, increased client budgets, a proactive approach to innovation, and the emergence of fundamental trends like biosimilars.

    Within this context, we expect to see continued growth for CMOs in the year ahead, perhaps even more rapid than the ~15% annual expansion of the industry as a whole. Data from our latest annual study, BioPlan Associates’ 12th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production [1], support analysis of some of the key trends relating to contract manufacturing.

    Trend No. 1: Outsourcing Budgets Are on the Upswing
    The clearest sign of a growing market is increasing budgets. And on this front, our annual studies have shown a strong turn of events in recent years.

    This year, biopharmaceutical manufacturers indicated that they would increase their spending on outsourced biopharmaceutical manufacturing by an average of 3.8%, keeping steady from last year’s forecast increase of 3.9%. These are compound increases, such that this year’s planned growth of 3.8% came on top of last year’s planned increase.

    To put this year’s budget increases in context, it’s roughly the same increase as manufacturers budgeted for operations for current products, new facility construction and hiring of new scientific staff. So while not in the top tier of budget expansions (those are reserved for new capital equipment, process development, innovation and operations staff), outsourcing growth is on par with other key budget items.

    Biomanufacturing has generally been immune to wider economic trends, such that budget contractions back in 2009 were not being implemented across the board. Yet when companies were facing those harsh economic realities, outsourcing was one of the 5 areas (of 12 we tested) planned for budget cuts. And just a few short years ago, in 2012, outsourcing was the only area set for a budget contraction.

    As outsourcing budgets grow, we have found fewer than 1 in 10 respondents expecting a decrease in these budgets, versus a majority predicting an increase. The overall average increase of 13% set for this year was on par with last year’s result (13.5%) and a step higher than 2013’s projected growth of 10.4%.

    Along with budget growth, our study demonstrated an increased willingness to use outsourcing as a method to cut costs. This was most pronounced in the following areas:
    • Outsourcing jobs in process development;
    • Outsourcing manufacturing to domestic service providers, more than double the proportion in 2011; and
    • Outsourcing manufacturing to non-domestic service providers, almost triple the proportion in 2011.
    In recent years, our study has found a more strategic element to the outsourcing calculus, as CMOs set themselves up as innovation leaders with access to sophisticated technology often not available at client companies. The growth of outsourcing as a cost-cutting measure can only add to its appeal. As such, we can expect outsourcing budgets to continue to grow, even if they don’t quite maintain the rapid increases of the past couple of years.

    Trend No. 2: CMOs Plan Capacity Expansions to Offset Current Crunches
    More than one-third—36%—of CMOs surveyed for our report said that their facility was experiencing “significant” or “severe” production capacity constraints. In a sense, our data had foreseen this problem: Last year, we warned that CMOs might face capacity constraints based on research that showed a large proportion of CMOs forecasting problems on the horizon. The level of constraints reported this year, though, were beyond what we might have expected, with “significant” constraints faced by roughly twice as many this year as last.

    What’s to blame? For one, CMOs are reaching the top of their capacity utilization rates. For example, in this year’s study CMOs were operating at 82% of mammalian cell culture operating capacity, versus 58% capacity utilization last year for that dominant paradigm.  Further, facility constraints were in fact CMOs’ most commonly cited reason for capacity crunches this year, followed by the physical capacity of downstream purification equipment.

    Not surprisingly, then, CMOs are squarely placing these constraints in their sights. And among CMOs, new capital equipment and new facility construction were the areas slated for the largest budget increases (>11%).

    CMOs predict that their mammalian cell culture capacity will grow by an impressive 77% over the next 5 years. That’s almost double the level of expansion they forecast last year. As a result, there’s less handwringing about future capacity constraints: the 1 in 5 expecting to face significant or severe constraints in 2020 is an encouraging result in light of the currently reporting bottleneck problems.

    In sum, our data show clearly that as the outsourcing market grows, CMOs are reaching critical levels of capacity utilization, and capacity constraints. To offset those constraints, CMOs are investing in new facilities and new capital equipment, and foresee some of their problems abating in the next few years. As a result, we might expect that next year’s data shows a slight lessening of capacity bottlenecks from this year, though it remains to be seen how quickly those investments pay off in this way.

    Trend No. 3: CMOs Looking to SUS, Downstream Advances for Performance Boost
    Facility upgrades and new capital equipment aren’t the only ways to avoid future capacity crunches: Improving downstream processing efficiency is also a key element. With downstream purification often blamed for bottlenecks, CMOs are hoping for downstream advances, and single-use equipment is often the area they first examine.

    In fact, the implementation and integration of single-use equipment ranks as the single biggest biomanufacturing trend for CMOs this year. These applications are being credited by many CMOs with performance gains. For example, we asked respondents which factors had created “significant” or “some” performance improvements at their facilities during the prior year, 86.4% of CMOs cited the use of disposable/single-use devices.

    Meanwhile, improved downstream production operations contributed to performance improvements for roughly two-thirds of CMOs. Single-use systems have a hand to play in downstream production operation improvements, too. Separately, when we asked CMOs about various measures they had taken to improve downstream purification operations, three-quarters (versus just 42% of biotherapeutic developers) reported investigating single-use disposable downstream technologies.

    With single-use devices appearing to be so beneficial to CMOs, it’s little wonder that these applications are high on CMOs’ list of desired technological advances. In terms of new product development, CMOs listed the following as their areas of greatest interest:
    • Disposable purification products (citing as a top-3 interest);
    • Chromatography products;
    • Disposable probes, sensors; and
    • Disposable bags and connectors.
    Trend No. 4:  Filling Jobs a Challenge: Process Development, Fill-Finish Opportunities Growing for CMOs
    Our study indicates that process development jobs are the most challenging for biomanufacturers to fill, and, correspondingly, that some companies are outsourcing these jobs not only to cut costs, but because in-house PD expertise is scarce. Nearly 40% of biomanufacturers are finding it difficult to fill positions in either up- or downstream process development. And the problem is most difficult among US respondents where nearly half of facilities are finding hiring a significant challenge.

    As a result, process development outsourcing has become more popular over the past few years. This year, 43% of respondents reported outsourcing upstream process development activities to at least some degree, up from 17.1% in 2010.  Further, the proportion of biomanufacturers who expect to outsource upstream and downstream process development activities at “significantly” higher levels in the near-term has been on the rise, reaching 17% of respondents for downstream and 12% for upstream process development. To be sure, these are still among the least-outsourced activities, both in breadth and depth. But the signs of growth are there.

    In examining fill-finish services in more detail, we discovered that more outsourcing of these activities ranked as one of the top trends identified by respondents. Other CMO-related trends in fill-finish (anecdotally) include:
    • CMOs introducing smaller filling machines for syringes or vials, specifically for Phase I and II clinical study supply;
    • CMOs using traditional RABs systems over isolators due to the need for flexibility and the high costs associated with isolator lines; and
    • Fill-Finish CMOs becoming larger, through mergers and acquisitions.
    Trend No. 5: A CMO’s Location No Longer Matters
    As CMOs compete to win new business across the above-mentioned (and other) areas, their physical location is ceasing to be a major selection factor. This year, just 1.5% of respondents indicated that a CMO being local to them was a “very important” issue to consider when considering outsourcing biomanufacturing. That was the lowest figure we’ve found to-date for a CMOs’ geographic proximity, and easily the lowest among the 19 criteria we measured.  Anecdotally, clients may still prefer to outsource locally, but as CMOs improve their client management and customer service performance, being on-site is no longer a necessity. 

    Instead of location, CMOs are being evaluated increasingly on issues such as compliance with companies’ quality standards, their ability to establish good working relationships, IP protection and having enough capacity to meet sales demand. (No wonder they are investing in more capacity!)

    Interestingly, as more companies consider off-shoring to be part of their future, US and European countries diverge when it comes to the international markets they consider appealing. For US companies, markets such as Singapore and China are among the top of the list as both potential outsourcing destinations and more positive “likely” destinations. But for Western European companies, the US and the UK appear to be hold the greatest appeal, with less consideration for emerging Asian markets.

    Trend No. 6: Biosimilars, Other Advances Creating Opportunities
    CMOs stand to benefit from the biosimilars pipeline as more than 40 blockbuster ($1 billion+) reference products see patent expirations over the next 5+ years.  Competition will increase, as over 80 biosimilars (attempt to) hit the markets.  While there are many large, marketing-capable biopharma companies intending to produce biosimilars, the majority are smaller R&D companies.  CMOs will, of courses, be necessary for this latter group. CMOs capable of efficient production stand to benefit.  Because U.S discounts are expected to reach at least 50%, with as many as 8 follow-ons per reference product, the competitive environment may be intense, and efficient manufacturing will be important.

    Europe has more than 20 biosimilars on the market and its regulatory issues are mostly resolved; but there has been relatively little overall market impact so far, with discounts averaging less than 30%. In the US the first formal approval (Zarxio/filgrastim-sndz, Sandoz/Novartis) is out, and more filings are coming.  The worldwide market is rapidly growing and we can expect $7-$10 billion in next 5 or more years of biosimilars and biobetters. 

    Biosimilars’ focus on efficiency will drive mainstream biologics innovation in efficiency and provide opportunities for savvy CMOs.  Outsourcing biosimilars is a likely model (e.g., Baxalta’s Genmab sale). And even Big Pharma may outsource some of its ‘less critical’ biosimilar development and manufacturing.  Biosimilars are a traditional fit for CMOs as they apply new technology to familiar products.  CMOs have needed expertise, facilities, critical regulatory know-how and can develop, scale-up and manufacture better and quicker than most developers. They can potentially make biosimilar APIs cheaper than doing in-house development, with better products and documentation.

    But biosimilars is a short term strategy, demanding more trials and more manufacturing. In the long-term it’s a zero-sum game, with essentially the same amount of drug product sold, in a given market.  Further, smaller biosimilar developers will hit roadblocks with clinical trials and limited capacity. Biosimilars are creating disruptive US opportunities and will require a strong focus on efficiency that will also drive mainstream biologics innovation.

    Looking Forward
    These are just some of the trends affecting CMOs today, but they are broadly indicative of the direction that the outsourcing market is taking.  Based on the results and trends identified in our study, we expect that the outsourcing market will continue to grow and benefit from increased budgets. More high-value operations such as process development, QbD and DoE are showing signs of increased outsourcing activity and are likely to be an ongoing trend.

    Meanwhile, CMOs themselves will likely focus on process efficiencies and handle potential bottleneck problems. Disposable downstream applications—where available—ought to be in high demand among CMOs, who continue to demonstrate their affinity for single-use equipment. We should also expect CMOs to be on the forefront of other emerging industry trends, such as the manufacture of biosimilars and the move towards modular facilities.


    Eric S. Langer
    BioPlan Associates

    Eric S. Langer is president and managing partner at BioPlan Associates, Inc., a biotechnology and life sciences marketing research and publishing firm established in Rockville, MD in 1989. He is editor of numerous studies, including “Biopharmaceutical Technology in China,” “Advances in Large-scale Biopharmaceutical Manufacturing”, and many other industry reports.  elanger@bioplanassociates.com  301-921-5979.  www.bioplanassociates.com

    References
    1. 12th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, BioPlan Associates, Inc. Rockville, MD., April 2015. www.bioplanassociates.com/12th
    Related Searches
    • events
    • biopharma companies
    • Manufacturing
    • outsourced
    Suggested For You
    The Ever-Evolving World of Combination Products The Ever-Evolving World of Combination Products
    Embedding Your Drug Strategy Within a Solid Foundation for Success Embedding Your Drug Strategy Within a Solid Foundation for Success
    Sepha Launches Small Batch Contract Packaging Service Sepha Launches Small Batch Contract Packaging Service
    A Potential “Marriage” A Potential “Marriage”
    Injectables Firms Expand Capacity Injectables Firms Expand Capacity
    TFF Expands Engagement with Experic TFF Expands Engagement with Experic
    India Emerges as Hot Spot for Manufacturing COVID-19 Vaccines India Emerges as Hot Spot for Manufacturing COVID-19 Vaccines
    The Pandemic’s Become an Insurmountable Opportunity The Pandemic’s Become an Insurmountable Opportunity
    Vetio Animal Health Vetio Animal Health
    Indian Generic Firms  Expand Biosimilar Portfolios Indian Generic Firms Expand Biosimilar Portfolios
    CMOs & Biosimilars Mfg. in the U.S. CMOs & Biosimilars Mfg. in the U.S.
    PBOA Praises Action On FDA Reauthorization  PBOA Praises Action On FDA Reauthorization
    Biosimilars Update Biosimilars Update
    Adents, Microsoft Present Serialization Solution Adents, Microsoft Present Serialization Solution
    Contract Manufacturing in the Supplement Industry Contract Manufacturing in the Supplement Industry

    Related Columns

    • Clinical Trials | Serialization | Supply Chain
      Anti-Counterfeiting in the Pharmaceutical Industry: An Evolution

      Anti-Counterfeiting in the Pharmaceutical Industry: An Evolution

      Keeping up with counterfeitors in the pharmaceutical industry is no easy task, but patients’ lives depend on it.
      Ben Locwin, Healthcare Science Advisors 10.04.19

    • Biosimilars
      The Bioprocessing Trek

      The Bioprocessing Trek

      Biosimilars are the next speed-bump for CMOs
      Emil W. Ciurczak, DoraMaxx Consulting 09.16.19

    • Clinical Trials
      Synthetic Control Arms

      Synthetic Control Arms

      In clinical trials, they don’t always capture the most important dimensions
      Ben Locwin 03.06.19


    • Biosimilars
      Know the Challenges of  Biosimilar Manufacturing

      Know the Challenges of Biosimilar Manufacturing

      Best practices for a competitive market
      Jerry Martin and Michiel Ultee 09.06.17

    • Biosimilars
      Indian Generic Firms  Expand Biosimilar Portfolios

      Indian Generic Firms Expand Biosimilar Portfolios

      With more players entering the ring, the race to enter the promising biosimilars market is getting hotter by the day in India
      S. Harachand, Contributing Editor 05.09.17

    • Biosimilars
      CMOs & Biosimilars Mfg. in the U.S.

      CMOs & Biosimilars Mfg. in the U.S.

      Biosimilars are moving from novel opportunity to mainstream product
      Eric S. Langer and Ronald A. Rader, BioPlan Associates 04.20.17


    • Biosimilars

      Biosimilars Update

      Fulfilling a dire need, but at what (human) cost?
      Ben Locwin, Contributing Editor 04.03.17

    • Biosimilars | Process Development

      Contract Manufacturing Budget Trends

      Study shows where the money is, and isn’t, flowing
      Eric S. Langer, BioPlan Associates 07.12.16

    • Clinical Trials | Process Development

      China Vaults to the Top of U.S. Biomanufacturers’ Off-Shoring Prospects

      A look at top destinations for future offshoring
      Eric S. Langer, BioPlan Associates 06.02.16


    • Clinical Trials

      Are More CRO Transactions Near?

      When will we see additional transactions involving the largest CROs?
      Chad Moore, Leerink Partners LLC 06.02.16

    • Biosimilars | Clinical Trials | Drug Discovery | Process Development

      Like the Temperature, It Feels Like Deal Activity is Heating Up

      A summary of 2016 transactions so far
      Chad Moore, Leerink Partners LLC 05.05.16

    • Analytical Services | Clinical Trials | Laboratory Testing | Supply Chain

      Analytical Instruments are On-Board with Outsourcing

      Newer process instruments are finally being designed with mobility in mind
      Emil W. Ciurczak, DoraMaxx Consulting 01.28.16


    • Biosimilars | Clinical Trials

      Outsourced Pharma Services: 2015 Review & 2016 Outlook

      ...
      Chad Moore, Leerink Partners 01.28.16

    • APIs | Biosimilars

      API and Intermediate Outsourcing Trends

      One thing’s for sure, when it comes to pharma trends there is no definitive trend
      Ben Locwin, Healthcare Science Advisors 10.07.15

    • Clinical Trials | Drug Development

      Recap of Notable Recent CRO Transactions

      Conditions are expected to remain favorable for M&A and capital markets activity in the pharmaceutical service and IT sector
      Chad Moore 10.07.15

    Trending
    • Sterling Pharma Solutions Acquires ADC Biotechnology
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • Alkermes, Merck Enter Clinical Trial And Supply Agreement
    • Ascendia Pharmaceuticals Poised For Expansion
    • Frontage Expands Capabilities At Its Clinical Site In Secaucus, NJ
    Breaking News
    • Bora Pharmaceuticals Adds Roller Compaction Capabilities
    • Ascendia Pharmaceuticals Poised for Expansion
    • Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    • Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    • AGC Biologics Appoints Jun Takami GM of Chiba Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Kyowa Hakko Launches Heat-Treated Probiotic Strain for Eye Health
    CGA-7 Green Coffee Extract by Vidya Herbs Achieves Self-Affirmed GRAS Status
    Nutritional Complex Evidenced to Reduce Preterm Birth
    Coatings World

    Latest Breaking News From Coatings World

    Barentz Expands Canadian CASE Team
    Shepherd Color Company Opens Sales Office in China
    Chromaflo Technologies Awarded Gold Status CSR Rating by EcoVadis in EMEA
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    CMS Establishes New Payment for Pelvalon’s Eclipse System
    Varian, Google Cloud Partner to Bring Convenience to Cancer Therapy
    Resonetics Leases New Manufacturing Space in Costa Rica
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    Ascendia Pharmaceuticals Poised for Expansion
    Bora Pharmaceuticals Adds Roller Compaction Capabilities
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Revlon Unveils New Fragrances Featuring Megan Thee Stallion & Sofia Carson
    Henkel Management Board Welcomes Wolfgang König
    Mielle Organics Gets a Major Investment
    Happi

    Latest Breaking News From Happi

    Nature’s Beauty Debuts Vegan Natural Body Care at Walgreens
    Estée Lauder Expands 'Beautiful' Fagrance Collection
    Mushrooms Are Key Ingredients in Beauty & Wellness
    Ink World

    Latest Breaking News From Ink World

    SE-DA Invests in Kornit Presto S
    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    Iron Oxide Pigments Market to Register 4.7% CAGR from 2021 to 2028: GVR
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Dantex elevates Joseph Sanchez to digital business development manager
    Mactac's Kevin Clunie joins TLMI panel
    MacDermid announces two new global sales roles
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Precision Textiles Offers Biodegradable Medical Fabric
    Northshore Launches Megamax Briefs in New Colors
    Essity Acquires Distribution Rights to Sorbact in Australia and New Zealand
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    New Biosealant Could Stabilize Cartilage, Boost Healing After Injury
    Google Executive Joins SeaSpine's Board of Directors
    HSS and LimaCorporate Open Provider-Based 3D Design and Printing Facility
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Tive Multi-sensor Tracker Solo 5G Relies on Sensirion SHT33
    VTT in 2020: Successful Year Despite Globally Challenging Times
    Lux Research: 3D Printing Market to Reach $51 Billion in 2030

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login